Financials data is unavailable for this security.
View more
Year on year DaShenLin Pharmaceutical Group Co Ltd grew revenues 15.45% from 21.25bn to 24.53bn while net income improved 12.63% from 1.04bn to 1.17bn.
| Gross margin | 33.80% |
|---|---|
| Net profit margin | 3.47% |
| Operating margin | 4.57% |
| Return on assets | 3.90% |
|---|---|
| Return on equity | 12.41% |
| Return on investment | 8.15% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at DaShenLin Pharmaceutical Group Co Ltd fell by 778.78m. However, the company earned 3.17bn from its operations for a Cash Flow Margin of 12.94%. In addition the company used 2.30bn on investing activities and also paid 1.65bn in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 6.03 |
|---|---|
| Tangible book value per share | 1.17 |
More ▼
Balance sheet in CNYView more
| Current ratio | 0.9178 |
|---|---|
| Quick ratio | 0.598 |
| Total debt/total equity | 1.76 |
|---|---|
| Total debt/total capital | 0.5981 |
More ▼
Growth rates in CNY
Year on year, growth in dividends per share fell -38.00% while earnings per share excluding extraordinary items rose 13.39%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 1.21% |
|---|---|
| Div growth rate (5 year) | 6.85% |
| Payout ratio (TTM) | 41.52% |
| EPS growth(5 years) | 15.88 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -34.16 |
More ▼
